泰格医药：2025年净利同比预增105%~204%

Core Viewpoint - The company, Tigermed (300347.SZ), expects a significant increase in net profit attributable to shareholders for 2025, projecting between 830 million to 1.23 billion RMB, representing a growth of 105% to 204% compared to the previous year [1] Financial Performance - The increase in profit is primarily due to a substantial rise in non-recurring gains and losses during the reporting period [1] - The company has seen a notable improvement in the disposal and holding gains of its non-current financial assets, which include equity stakes in non-listed companies, shares in listed companies, and pharmaceutical funds [1] Industry Context - The recovery of the Chinese innovative drug industry has contributed to the restoration of asset values [1] - The company has achieved good growth in both the number and value of new orders compared to the same period last year [1] Order Growth - For 2025, the company anticipates net new orders (newly signed orders minus canceled orders) to be in the range of 9.5 billion to 10.5 billion RMB, compared to 8.42 billion RMB in net new orders for the same period in 2024 [1]